

# CURRICULUM VITAE

April 2018



---

**Title and name**

Prof Ursula Gundert-Remy

---

**Nationality**

German

---

---

**Panel / Scientific Committee**

Panel on Food Additives and Flavourings (FAF)

---

---

**Education**

Habilitation in Internal Medicine and Clinical Pharmacology, 1979, Medical Faculty, University of Heidelberg

PhD in Human medicine, 1969, Universität Heidelberg

State Examination (Medizinisches Staatsexamen), 1969, University of Heidelberg, Germany

---

**Work Experience**

2008 - present	Retirement	Working as expert for EFSA Research (PBTK modelling; QSAR; TTC) Teaching (medical students)
1996 – 2008	Federal Institute for Risk Assessment (BfR), , Berlin, Germany	Department Head; Health Risk Assessment of Industrial Chemicals, Pesticides, Biocides within the European Framework Research (toxicogenomics; non-hepatic metabolism; PBTK modelling)
1993-1996	University of Goettingen, Germany	Chair and Full Professor, Dept. Clinical Pharmacology Research (kinetic and dynamic of selected drugs, such as morphine, paracetamol; polymorphism in metabolic enzymes Clinical services (drug monitoring)
1984-1992	Federal Health Office, Berlin, Germany	Head, Dept. Clinical and Experimental Pharmacology, Institute for Drugs Assessment of Efficacy and Safety of Drugs; Risk Assessment (Pharmacovigilance) - Research (kinetic and dynamic of selected drugs, such as theophylline, fenoterol; biomonitoring; - Polymorphism in metabolic enzymes

1980-1983	University of Heidelberg, Germany	Department Clinical Pharmacology Senior Clinician, Deputy Head, Dep. Clinical Pharmacology - Patient care (cardiology, infectiology, general internal medicine) - Research ( see above) - Teaching (medical students)
1979-1980	Biocenter, Basel, Switzerland	Guest Scientist Research (kinetic, metabolism and dynamic of atropine; kinetics and dynamic modelling)
1975-1979	University of Heidelberg, Germany Department Internal Medicine, University Hospital	Junior Clinician - Patient care (cardiology, infectiology, general internal medicine) - Research ( see above) - Teaching (medical students)
1970-1974	University of Heidelberg, Germany Department Clinical Pharmacology,	Junior researcher - Research ( drug analytics, kinetics in animals, kinetics and dynamics in humans, modelling, bioavailability) - Teaching (medical students)

---

### Scientific expertise

- Chemical/Toxicological Risk Assessment
- Dose-Response Modelling
- (Mammalian) Toxicology
- Toxicokinetics and Metabolism
- Organ specific metabolism
- Physiologically based toxicokinetics
- Toxicokinetic modelling
- Mode of action (MOA) / Adverse outcome pathway (AOP)
- Modelling of effects/toxicodynamics
- Alternative methods in risk assessment

---

### Most relevant scientific publications within the fields of EFSA

Author of 190 peer-reviewed papers. Main areas of research include kinetic and metabolism; dose-concentration- response analysis; risk assessment; non-animal methods

Degen GH, Ali N, **Gundert-Remy U**, 2018. Preliminary data on citrinin kinetics in humans and their use to estimate citrinin exposure based on biomarkers. *Toxicol Lett.* 282:43-48. doi: 10.1016/j.toxlet.2017.10.006.

Degen GH, Partosch F, Muñoz K, **Gundert-Remy U**, 2017. Daily uptake of mycotoxins - TDI might not be protective for nursed infants. *Toxicol Lett.* 277:69-75. doi: 10.1016/j.toxlet.2017.06.002

---

Testai E; Hartemann P, Rodríguez-Farre E, Rastogi SC, Bustos J, **Gundert-Remy U**, Hensten A, Kopperud HM, Olea N, Piersma A, De Jong W, 2016. The safety of the use of bisphenol A in medical devices. *Regul Toxicol Pharmacol*. Aug;79:106-7. doi: 10.1016/j.yrtph.2016.01.014

Partosch F, Mielke H, Stahlmann R, Kleuser B, Barlow S, **Gundert-Remy U**, 2015. Internal threshold of toxicological concern values: enabling route-to-route extrapolation. *Arch Toxicol*. 89(6):941-8. doi: 10.1007/s00204-014-1287-6

Partosch F, Mielke H, Stahlmann R, **Gundert-Remy U**, 2015. Caffeine intake in pregnancy: relationship between internal exposure and effect on birth weight. *Food Chem Toxicol*. 86:291-7. doi: 10.1016/j.fct.2015.11.005

**Gundert-Remy U**, Damm G, Foth H, Freyberger A, Gebel T, Golka K, Röhl C, Schupp T, Wollin KM, Hengstler JG, 2015. High exposure to inorganic arsenic by food: the need for risk reduction. *Arch Toxicol* 89(12):2219-27. doi: 10.1007/s00204-015-1627-1

Bessemers JG, Loizou G, Krishnan K, Clewell HJ 3rd, Bernasconi C, Bois F, Coecke S, Collnot EM, Diembeck W, Farcal LR, Geraets L, **Gundert-Remy U**, Kramer N, Küsters G, Leite SB, Pelkonen OR, Schröder K, Testai E, Wilk-Zasadna I, Zaldívar-Comenges JM, 2014. PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. *Regul Toxicol Pharmacol*. 68(1):119-39. doi: 10.1016/j.yrtph.2013.11.008.

Partosch F, Mielke H, **Gundert-Remy U**, 2013. Functional UDP-glucuronyltransferase 2B15 polymorphism and bisphenol A concentrations in blood: results from physiologically based kinetic modelling. *Arch Toxicol*. 87(7):1257-64. doi: 10.1007/s00204-013-1022-8.

**Gundert-Remy U**, Mielke H, Bernauer U, 2013. Commentary: dermal penetration of bisphenol A--consequences for risk assessment. *Toxicol Lett*. 217(2):159-61. doi: 10.1016/j.toxlet.2012.12.009

Schug M, Stöber R, Heise T, Mielke H, **Gundert-Remy U**, Godoy P, Reif R, Blaszkewicz M, Ellinger-Ziegelbauer H, Ahr HJ, Selinski S, Günther G, Marchan R, Blaszkewicz M, Sachinidis A, Nüssler A, Oberemm A, Hengstler JG, 2013 Pharmacokinetics explain in vivo/in vitro discrepancies of carcinogen induced gene expression alterations in rat liver and cultivated hepatocytes. *Arch Toxicol*.;87(2):337-45. doi: 10.1007/s00204-012-0999-8

Mielke H, **Gundert-Remy U**, 2012. Physiologically based toxicokinetic modelling as a tool to support risk assessment: three case studies. *J Toxicol* :359471. <http://dx.doi.org/10.1155/2012/359471>

Kalkhof H, Herzler M, Stahlmann R, **Gundert-Remy U**, 2012. Threshold of toxicological concern values for non-genotoxic effects in industrial chemicals: re-evaluation of the Cramer classification. *Arch Toxicol*. 86(1):17-25. doi: 10.1007/s00204-011-0732-z

Mielke H, Abraham K, Götz M, Vieth B, Lampen A, Luch A, **Gundert-Remy U**, 2011. Physiologically based toxicokinetic modelling as a tool to assess target organ toxicity in route-to-route extrapolation--the case of coumarin. *Toxicol Lett*.202(2):100-10. doi: 10.1016/j.toxlet.2011.01.022

Rupp B, Appel KE, **Gundert-Remy U**, 2010. Chronic oral LOAEL prediction by using a commercially available computational QSAR tool. *Arch Toxicol*.84(9):681-8. doi: 10.1007/s00204-010-0532-x

Oberemm A, Ahr HJ, Bannasch P, Ellinger-Ziegelbauer H, Glückmann M, Hellmann J, Ittrich C, Kopp-Schneider A, Kramer PJ, Krause E, Kröger M, Kiss E, Richter-Reichhelm HB, Scholz G, Seemann K, Weimer M, **Gundert-Remy U**, 2009. Toxicogenomic analysis of N-nitrosomorpholine induced

changes in rat liver: comparison of genomic and proteomic responses and anchoring to histopathological parameters. *Toxicol Appl Pharmacol.* 241(2):230-45. doi: 10.1016/j.taap.2009.08.020

Mielke H, **Gundert-Remy U**, 2009. Bisphenol A levels in blood depend on age and exposure. *Toxicol Lett.* 190(1):32-40. doi: 10.1016/j.toxlet.2009.06.861

Settels E, Bernauer U, Palavinskas R, Klaffke HS, **Gundert-Remy U**, Appel KE, 2008. Human CYP2E1 mediates the formation of glycidamide from acrylamide. *Arch Toxicol.* 82(10):717-27. doi: 10.1007/s00204-008-0296-8.

---